Leprosy - Evolution of the path to eradication

Indian Journal of Medical Research

Volumn 137, Issue 1, 2013, Pages 15-35

  Dogra, Sunil ^a   Narang, Tarun ^a   Kumar, Bhushan ^a,b  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b NONE   (India)

Author keywords

Deformity; Hansen's disease; Leprosy; MDT; Multibacillary; Mycobacterium leprae; Paucibacillary; Reconstructive surgery

Indexed keywords

CHAULMOOGRA OIL; CLARITHROMYCIN; CLOFAZIMINE; CORTICOSTEROID; DAPSONE; ETHIONAMIDE; ISONIAZID; MINOCYCLINE; MOXIFLOXACIN; OFLOXACIN; PREDNISOLONE; PROTIONAMIDE; RIFAMPICIN; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE; UNCLASSIFIED DRUG; VEGETABLE OIL;

CHEMOPROPHYLAXIS; DISEASE ERADICATION; DISEASE TRANSMISSION; FOLLOW UP; HEALTH PRACTITIONER; HUMAN; LEPROMIN TEST; LEPROSY; MYCOBACTERIUM LEPRAE; NAUSEA; NERVE INJURY; NONHUMAN; PAUCIBACILLARY LEPROSY; PREVALENCE; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RISK FACTOR; SKIN DEFECT; STIGMA; STOMACH IRRITATION; TUBERCULOSIS;

EID: 84874696958     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (117)

1. Pandya SS. Historical background. In: Kar HK, Kumar B, editors. IAL textbook of leprosy. New Delhi: Jaypee; 2008. p. 1-18.
2. World Health Organization. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities (plan period: 2006-2010). Geneva: WHO; 2005.
3. Bhattacharya SN, Sehgal VN. Reappraisal of the drifting scenario of leprosy multi-drug therapy: new approach proposed for the new millennium. Int J Dermatol 2002; 41: 321-6.
4. Becx-Bleumink M. Duration of multi-drug therapy in paucibacillary leprosy patients; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation training Center (ALERT) in Ethiopia. Int J Lepr 1992; 60: 436-44.
5. Becx-Bleumink M. Relapses amongst leprosy patients treated with multi-drug therapy; experience in the leprosy control program of the All Africa Leprosy and Rehabilitation Training Center (ALERT) in Ethiopia; practical difficulties with diagnosing relapses; operational procedures and criteria for diagnosing relapses. Int J Lepr 1992; 60: 421-35.
6. Bhattacharya SN, Sehgal VN. Leprosy in India. Clin Dermatol 1999; 17: 159-70.
7. World Health Organization. Global leprosy situation 2012. Wkly Epidemiol Record 2012; 34: 317-28.
8. Dowdle WR. The principles of disease elimination and eradication. Bull World Health Organ 1998; 76: 22-5.
9. Patro BK, Madhanraj K, Singh A. Is leprosy 'Elimination' a conceptual illusion? Indian J Dermatol Venereol Leprol 2011; 77: 549-51.
10. Robbins G, Tripathy VM, Misra VN, Mohanty RK, Shinde VS, Gray KM. et al. Ancient skeletal evidence for leprosy in India (2000 B.C.). PLoS One 2009;
11. Monot M, Honore N, Garnier T, Araoz R, Coppée JY, Lacroix C, et al. On the origin of leprosy. Science 2005; 308: 1040-2.
12. Browne SG. The history of leprosy. In: Hastings RC, editor. Leprosy, 1st ed. Edinburgh: Churchill Livingstone; 1985. p. 1-14.
13. Trautman JR. A brief history of Hansen's disease. Star 1990; 50: 3-16.
14. Gussow Z. Leprosy, racism and public health: social policy in chronic disease control. Boulder, Colo: Westview Press; 1989.
15. Awofeso N. Leprosy control, public health paradigms and stigma. Aust NZ J Public Health 2011; 35: 9-11.
16. Jacob JT, Franco-Paredes C. The stigmatization of leprosy in India and its impact on future approaches to elimination and control. PLoS Negl Trop Dis 2008; 2: e113.
17. Short RA. The Bible and modern medicine. London: Paternoster Press; 1953. p. 77.
18. Feeny P. The fight against leprosy. New York: American Leprosy Missions; 1964.
19. Brown W. Can social marketing approaches change community attitudes towards leprosy? Lepr Rev 2006; 77: 89-98.
20. Bennett BH, Parker DL, Robson M. Leprosy: Steps along the journey of eradication. Public Health Rep 2008; 123: 198-205.
21. Carter HV. On leprosy and elephantiasis. Eyre and Spottiswoode; 1874. p.
22. Carter HV. "Note on the Pathology of Leprosy", Maharashtra State Archives General Department, Publication No: 14494, Appendix p. 7, 1883.
23. Lockwood DNJ, Sarno E, Smith WC. Classifying leprosy patients - searching for the perfect solution? Lepr Rev 2007; 78: 317-20.
24. Dharmendra, Leprosy Classification. In: Hastings RC, editor. Leprosy, 2nd ed. Edinburgh: Churchill-Livingstone; 1994.
25. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobact Dis 1966; 34: 255-73.
26. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev 2006; 19: 338-81.
27. Montoya D, Modlin RL. Learning from leprosy: Insight into the human innate immune response. Adv Immunol 2010; 105: 1-24.
28. Skinsnes OK. Origin of chaulmoogra oil - another version. Int J Lepr 1972; 40: 172-3.
29. Bhishagratna KK. The Sushruta Samhita, vol. II. Varanasi: Chowkhamba Sanskrit Series Office; 1963. p. 36-40.
30. WHO. Chemotherapy of leprosy for control programmes. WHO Tech Rep Ser No.675. Geneva: WHO; 1982. p. 1-33.
31. Rogers L. The treatment of leprosy, Indian Medical Gaz, April 1920, 4: 125-8.
32. Cochrane RG. A comparison of sulphone and hydnocarpus therapy of leprosy. Int J Lepr 1948; 16: 139-44.
33. Anonymous. Chemotherapy of leprosy. Report of a WHO Study Group. WHO Tech Rep Ser Geneva: WHO; 1994. p. 1-24.
34. Pettit JHS, Rees RJW. Studies on sulphone resistance in leprosy. An experimental and clinical study. Lancet 1964; 26: 673-4.
35. Pearson JM, Haile GS, Rees RJ. Primary dapsone resistant leprosy. Lepr Rev 1977; 48: 129-32.
36. Sansarricq H. Leprosy in the world today. Lepr Rev 1981; 52: 15-31.
37. Pettit JH, Rees RJ. Studies in sulfone resistance in leprosy with the riminophenazine derivative B Int J Lepr 1966; 34: 391-7.
38. Waters MF, Laing AB, Rees RJ. Proven primary dapsone resistance in leprosy- a case report. Lepr Rev 1978; 49: 127-30.
39. World Health Organization. Report of the third meeting of the Scientific Working Group (SWG) on the Chemotherapy of leprosy (THELEP), document TDR/THELEP-SWG/80.3; 1980.
40. Gautam VP. Treatment of leprosy in India. J Postgrad Med 2009; 55: 220-4.
41. Sehgal VN, Sardana K, Dogra S. The imperatives of leprosy treatment in the pre- and post-global leprosy elimination era: Appraisal of changing the scenario to current status. J Dermatol Treat 2008; 19: 82-91.
42. Levy L, Shepard CC, Fasal P. The bactericidal effect of rifampicin on M. leprae in man: A) single doses of 600, 900 and 1200 mg; and b) daily doses of 300 mg. Int J Lepr Other Mycobact Dis 1976; 44: 183-7.
43. Browne SG, Hogerzeil LM. "B-263" in the treatment of leprosy: Preliminary report of pilot trial. Lepr Rev 1962; 33: 6-10.
44. Rees RJ, Pearson JM, Waters MF. Experimental and clinical studies on rifampicin in the treatment of leprosy. Br Med J 1970; 1: 89-92.
45. Leiker DL, Kamp H. First results of treatment of leprosy with Rifadin. Lepr Rev 1970; 41: 25-30.
46. Minutes of the seventh meeting of the Steering Committee of the Chemotherapy of Leprosy (THELEP) Scientific Working Group, Geneva, April 24-25, 1980. Geneva, World Health Organization (restricted document). Annex: General protocol for field trials of chemotherapy of multibacillary leprosy.
47. W47. HO expert committee on leprosy. 6th Report, WHO Tech Rep Ser No. Geneva: WHO; 1988.
48. W48. HO expert committee on leprosy. 7th Report 9 WHO Tech Report Ser No. Geneva: WHO; 1998.
49. Richardus JH, Habbema JDF. The impact of leprosy control on the transmission of M. leprae: is elimination being attained? Lepr Rev 2007; 78: 330-7.
50. Meima A, Gupte MD, van Oortmarssen GJ, Habbema JD. Trends in leprosy case detection rates. Int J Lepr Other Mycobact Dis 1997; 65: 305-19.
51. Fine PE, Warndorff DK. Leprosy by the year 2000 - what is being eliminated? Lepr Rev 1997; 68: 201-2.
52. Smith WC. We need to know what is happening to the incidence of leprosy. Lepr Rev 1997; 68: 195-200.
53. Anonymous. Report of the International Leprosy Association Technical Foum. 25-28 February 2002. Paris, France. Lepr Rev 2002; 73 (Suppl): S3-61.
54. Meima A, Richardus JH, Habbema JD. Trends in leprosy case detection worldwide since 1985. Lepr Rev 2004; 75: 19-33.
55. Ji B, Jamet P, Perani EG, Sow S, Lienhardt C, Petinon C, et al. Bactericidal activity of single dose of clarithromycin plus minocycline, with or without ofloxacin, against Mycobacterium leprae in patients. Antimicrob Agents Chemother 1996; 40: 2137-41.
56. Banerjee DK, McDermott-Lancaster RD, McKenzie S. Experimental evaluation of possible new short-term drug regimens for treatment of multibacillary leprosy. Antimicrob Agents Chemother 1997; 41: 326-30.
57. Ji B, Grosset JH. Combination of rifapentine - moxifloxacin-minocycline (PMM) for the treatment of leprosy. Lepr Rev 2000; 71 (Suppl): 581-7.
58. Daumerie D. Current World Health Organization-sponsored studies in the chemotherapy of leprosy. Lepr Rev 2000; 71: S88-90.
59. Ji B. Prospects for chemotherapy of leprosy. Indian J Lepr 2000; 72: 187-98.
60. Pattyn SR. Search for effective short-course regimen for the treatment of leprosy. Int J Lepr 1993; 61: 76-81.
61. Pattyn S, Grillone S. A 6 weeks quadruple drug regimen for the treatment of multi-bacillary leprosy. Lepr Rev 2000; 71: 43-6.
62. Grosset JH. The new challenges for chemotherapy research. Lepr Rev 2000; 71 (Suppl): 100-4.
63. Joshi PL. National Leprosy Eradication Programme and new paradigms; In: Kar HK, Kumar B, editors. IAL textbook of leprosy. New Delhi: Jaypee; 2008. p. 35-43.
64. Desikan KV. Elimination of leprosy & possibility of eradication - the Indian scenario. Indian J Med Res 2012; 135: 3-5.
65. WHO/SEARO. Regional strategy for sustaining leprosy services and further reducing the burden of leprosy - 2006-2010. SEA-LEP-162. 2009. p. 1-21.
66. World Health Organization. Enhanced global strategy for further reducing the disease burden due to leprosy 2011-2015. SEAGLP- 2009. p.
67. Jacob JT, Franco-Paredes C. The stigmatization of leprosy in India and its impact on future approaches to elimination and control. PLoS Negl Trop Dis 2008; 30: e113.
68. Becx-Bleumink M, Berhe, D. Occurrence of reactions, their diagnosis and management in leprosy patients treated with multidrug therapy: experience in the Leprosy Control Program of the All Africa leprosy and Rehabilitation Training Center (ALERT) in Ethiopia. Int J Lepr Other Mycobact Dis 1992; 60: 173-84.
69. Lienhardt C, Fine, PEM. Type 1 reaction, neuritis and disability in leprosy. What is the current epidemiological situation? Lepr Rev 1994; 65: 9-33.
70. Van brakel WH, Khawas IB, Lucas S. Reactions in leprosy: an epidemiological study of 386 patients in West Nepal. Lepr Rev 1994; 65: 190-203.
71. Kumar B, Dogra S, Kaur I. Epidemiological characteristics of leprosy reactions: 15 years experience from north India. Int J Lepr Other Mycobact Dis 2004; 72: 125-33.
72. Van Veen NH, Lockwood DN, Van Brakel WH, Ramirez J Jr, Richardus JH. Interventions for erythema nodosum leprosum. A Cochrane review. Lepr Rev 2009; 80: 355-72.
73. Shetty VP, Khambati FA, Ghate SD, Capadia GD, Pai VV, Ganpati R, et al. The effect of corticosteroids usage on bacterial killing, clearance and nerve damage in leprosy; Part 3 - Study of two comparable groups of 100 multibacillary (MB) patients each, treated with MDT + steroids versus MDT alone, assessed at 6 months post-release from 12 months MDT. Lepr Rev 2010; 81: 41-58.
74. van Veen NH, Nicholls PG, Smith WC, Richardus JH. Corticosteroids for treating nerve damage in leprosy. A Cochrane review. Lepr Rev 2008; 79: 361-71.
75. Saunderson P, Bizuneh E, Leekassa R. Neuropathic pain in people treated for multibacillary leprosy more than ten years previously. Lepr Rev 2008; 79: 270-6.
76. Mahato ME. Disability prevention and medical rehabilitation (DPMR) - prevention of disability and timely referral in leprosy. J Indian Med Assoc 2006; 104: 682-5.
77. NLEP-Operational guidelines. Disability prevention & medical rehabilitation. New Delhi: Central Leprosy Division, Directorate General of Health Services; 2007.
78. Ganapati R, Pai VV. Community based comprehensive leprosy work. In: Kar HK, Kumar B, editors. IAL textbook of leprosy. New Delhi: Jaypee; 2008. p. 538-44.
79. Bakker L, Van Brakel WH. Empowerment assessment tools in people with disabilities in developing countries. A systematic literature review. Lepr Rev 2012; 83: 129-53.
80. Awofeso N, Rammohan A. Community arts and health advocacy in HIV/AIDS activism. Hektoen Int 2010. Available from: http://www.hektoeninternational.org/kindredparadigms_ AIDSadvocacy.html, accessed on October 18, 2012.
81. Shetty VP. Challenges facing the control of leprosy in the Indian context. Ann Acad Med Singapore 2010; 39: 1-3.
82. Sharma A, Sharma VK, Rajwanshi A, Das A, Kaur I, Kumar B. Presence of M. laeprae in tissues in slit skin smear negative multibacillary (MB) patients after WHO-MBR. Lepr Rev 1999; 70: 281-6.
83. Maeda S, Matsuoka M, Nakata N, Kai M, Maeda Y, Hashimoto K, et al. Multidrug resistant Mycobacterium leprae from patients with leprosy. Antimicrob Agents Chemother 2001; 45: 3635-9.
84. Shetty VP, Wakade AV, Ghate S, Pai VV, Ganapati R, Antia NH. Viability and drug susceptibility testing of M. leprae using mouse footpad in 37 relapse cases of leprosy. Int J Lepr Other Mycobact Dis 2003; 71: 210-7.
85. Honor N, Cole ST. Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother 1993; 37: 414-8.
86. Cambau E. Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin Infect Dis 2002; 34: 39-45.
87. Matsuoka M, Kashiwabara Y, Namisato M. A Mycobacterium leprae isolate resistant to dapsone, rifampin and sparfloxacin. Int J Lepr Other Mycobact Dis 2000; 68: 452-5.
88. Matsuoka M, Budiawan T, Aye KS, Kyaw K, Tan EV, Cruz ED, et al. The frequency of drug resistance mutations in Mycobacterium leprae isolates in untreated and relapsed patients from Myanmar, Indonesia and the Philippines. Lepr Rev 2007; 78: 343-52.
89. WHO. Guidelines for global surveillance of drug resistance in leprosy. SEA-GLP-2009.2. Geneva: WHO; 2009.
90. Prasad P, Kaviarasan PK. Leprosy therapy, past and present: Can we hope to eliminate it? Indian J Dermatol 2010; 55: 316-24.
91. Cunha SS, Alexander N, Barreto ML, Pereira ES, Dourado I, Maroja Mde F, et al. BCG revaccination does not protect against leprosy in the Brazilian amazon: A cluster randomized trial. PLoS Negl Trop Dis 2008; e167.
92. Gillis TP, Reed SG. Advances and hurdles on the way toward a leprosy vaccine. Hum Vaccin 2011; 7: 1172-83.
93. Talwar GP, Zaheer SA, Mukherjee R, Walia R, Misra RS, Sharma AK, et al. Immunotherapeutic effects of a vaccine based on a saprophytic cultivable mycobacterium, Mycobacterium w in multibacillary leprosy patients. Vaccine 1990; 8: 121-9.
94. Katoch K, Katoch VM, Natrajan M, Sreevatsa, Gupta UD, Sharma VD, et al. 10-12 years follow-up of highly bacillated BL/LL leprosy patients on combined chemotherapy and immunotherapy. Vaccine 2004; 22: 3649-57.
95. Kaur I, Dogra S, Kumar B, Radotra BD. Combined 12-month WHO/MDT MB regimen and Mycobacterium w. vaccine in multibacillary leprosy: a follow-up of 136 patients. Int J Lepr Other Mycobact Dis 2002; 70: 174-81.
96. Narang T, Kaur I, Kumar B, Radotra BD, Dogra S. Comparative evaluation of immunotherapeutic efficacy of BCG and Mw vaccines in patients of borderline lepromatous and lepromatous leprosy. Int J Lepr Other Mycobact Dis 2005; 73: 105-14.
97. Rao PN, Lakshmi TS. Final push of leprosy in India: What is being pushed? Indian J Dermatol Venereol Leprol 2005; 71: 226-9.
98. Fine PE. Leprosy′s global statistics- still room for improvement. Lepr Rev 2008; 79: 235-8.
99. Molyneux DH, Hopkins DR, Zagaria N. Disease eradication, elimination and control: The need for accurate and consistent usage. Trends Parasitol 2004; 20: 347-51.
100. Lockwood DN, Suneetha S. Leprosy: Too complex a disease for a simple elimination paradigm. Bull World Health Organ 2005; 83: 230-5.
101. Braber KL. An evaluation of GAEL, the Global Alliance for the Elimination of Leprosy. Lepr Rev 2004; 75: 208-13.
102. Durston T. What lessons can we learn from the evaluation of GAEL? Lepr Rev 2004; 75: 214-6.
103. Ji B. Comments on the report entitled 'Independent evaluation of the Global Alliance for the Elimination of Leprosy'. Lepr Rev 2004; 75: 217-20.
104. Smith C, Richardus JH. Leprosy strategy is about control, not eradication. Lancet 2008; 371: 969-70.
105. Awofeso N. The place of leprosy in the control-elimination-105. eradication spectrum. Bull World Health Organ 2005; 83: 558.
106. Smith WCS. Sustaining anti-leprosy activities requires radical changes. Lepr Rev 2010; 81: 281-3.
107. Lunau Y. Sustainability in fighting leprosy - revitalising high ambitions. Lepr Rev 2010; 81: 284-6.
108. Feenstra P. Sustainability of leprosy control services in low endemic situations. Int J Lepr 1994; 62: 599-608.
109. Molyneux DH. "Neglected" diseases but unrecognized successes-challenges and opportunities for infectious disease control. Lancet 2004; 364: 380-3.
110. Saunderson PR. Leprosy elimination: Not as straightforward as it seemed. Public Health Rep 2008; 123: 213-6.
111. Curtiss R, Blower S, Cooper K, Russell D, Silverstein S, Young L. Leprosy research in the post-genome era. Lepr Rev 2001; 72: 8-22.
112. Rodrigues LC, Lockwood DNJ. Leprosy now: epidemiology, progress, challenges, and research gaps. Lancet Infect Dis 2011; 11: 464-70.
113. Li J, Mu H, Ke W. The sustainability of self-care in two counties of Guizhou Province, Peoples' Republic of China. Lepr Rev 2008; 79: 110-7.
114. Madhavan K, Vijayakumaran P, Ramachandran L, Manickam C, Rajmohan R, Mathew J, et al. Sustainable leprosy related disability care within integrated general health services: findings from Salem District, India. Lepr Rev 2007; 78: 353-61.
115. Bakker MI, Scheelbeek PFD, Van Beers SM. The use of GIS in leprosy control. Lepr Rev 2009; 80: 327-31.
116. Vlassoff C, Khot S, Rao S. Double jeopardy: women and leprosy in India. World Health Stat Q 1996; 49: 120-6.
117. A/HRC/15/30, annex: (English). Available from: http://www.ilep.org.uk/fileadmin/uploads/Documents/ News_documents/Principles_and_Guidelines_FINAL_English.pdf, accessed on October 20, 2012.